[Market Focus] Ildong Pharmaceutical Surges Over 5% on Positive Obesity Drug Clinical Results

Ildong Pharmaceutical rose nearly 6% in early trading on the 24th. Investor sentiment appears to have improved following analysis that clinical data for its oral GLP-1 obesity treatment under development is showing positive results.

As of 9:27 a.m. on this day, Ildong Pharmaceutical's stock price on the Korea Exchange was up 5.83% from the previous trading day, trading at 22,800 won. The stock opened at 23,700 won and at one point rose to 23,800 won.

On this day, IV Research stated, "The pipeline that provides the greatest upside to Ildong Pharmaceutical's corporate value is the oral GLP-1 new drug 'ID110521156,'" and added, "The small-molecule oral GLP-1 new drug that Ildong Pharmaceutical has been developing since 2023 has shown competitive interim results in domestic Phase 1 clinical trials, conducting both single ascending dose (SAD) and multiple ascending dose (MAD) studies."

The firm continued, "According to the disclosed clinical data, the average weight loss rate was -5.50% at a low dose (50mg) and -6.89% at a medium dose (100mg), with a maximum of -11.9%." It also noted, "No cases of hepatotoxicity were observed, and there were no reports of trial discontinuation due to gastrointestinal side effects." The company further emphasized, "These results are comparable to the data for Orforglipron, developed by Eli Lilly, which is currently leading the small-molecule GLP-1 field."